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A B S T R A C T
Background: An inter-arm systolic blood pressure difference (IAD) is associated with cardiovascular
disease. The aim of this study was to develop and validate the optimal cut-off value of IAD as a predictor
of major adverse cardiac events in patients with arteriosclerosis risk factors.
Methods: From 2009 to 2014, 1076 patients who had at least one cardiovascular risk factor were included
in the analysis. We deﬁned 700 randomly selected patients as a development cohort to conﬁrm that IAD
was the predictor of cardiovascular events and to determine optimal cut-off value of IAD. Next, we
validated outcomes in the remaining 376 patients as a validation cohort. The blood pressure (BP) of both
arms measurements were done simultaneously using the ankle-brachial blood pressure index (ABI) form
of automatic device. The primary endpoint was the cardiovascular event and secondary endpoint was the
all-cause mortality.
Results: During a median period of 2.8 years, 143 patients reached the primary endpoint in the
development cohort. In the multivariate Cox proportional hazards analysis, IAD was the strong predictor
of cardiovascular events (hazard ratio: 1.03, 95% conﬁdence interval: 1.01–1.05, p = 0.005). The receiver
operating characteristic curve revealed that 5 mmHg was the optimal cut-off point of IAD to predict
cardiovascular events (p < 0.001). In the validation cohort, the presence of a large IAD (IAD 5 mmHg)
was signiﬁcantly associated with the primary endpoint (p = 0.021).
Conclusions: IAD is signiﬁcantly associated with future cardiovascular events in patients with
arteriosclerosis risk factors. The optimal cut-off value of IAD is 5 mmHg.
© 2017 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Cardiovascular disease is a major health problem, accounting
for 30% of all deaths in Asian countries [1]. This disease is a health
problem that demands a clinical approach to prevention, early
detection, and monitoring of the progression of the disease.* Corresponding author at: Department of Cardiovascular Medicine, Tokushima
University Hospital, 2-50-1 Kuramoto 770-0003, Tokushima, Japan.
E-mail address: kusunosek@tokushima-u.ac.jp (K. Kusunose).
http://dx.doi.org/10.1016/j.jjcc.2017.06.010
0914-5087/© 2017 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsArteriosclerosis is a major contributor to the development of
cardiovascular disease and is a major cause of mortality and
morbidity [2,3]. Measurement of blood pressure (BP) is the most
frequently and simplest method to assess the activity of
arteriosclerosis [4]. In the clinical setting, cases with a difference
of BP were found occasionally [5,6]. Meta-analyses reported that a
difference in systolic BP of 10 mmHg or more between both arms
was associated with development of cardiovascular events [7–
9]. However, the cut-off value of 10 mmHg or 15 mmHg seems to
be an equivocal index because of limited evidence [10]. The
optimal cut-off value of inter-arm systolic blood pressure reserved.
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events. The aim of this study was to develop and validate the
optimal cut-off value of IAD as a predictor of major adverse
cardiovascular events in patients with arteriosclerosis risk factors.
Methods
Study design and data collection
This was a single center prospective observational study. A total
of 1160 patients consulted Tokushima Prefectural Miyoshi Hospi-
tal, from April 2009 to December 2014, who received a medical
service under health insurance. We included patients with at least
one or more arteriosclerotic risk factors. Risk factors were diabetes
mellitus, hypertension, dyslipidemia, smoking history, history of
coronary artery disease, history of cerebrovascular disease, or
history of peripheral arterial disease [11]. The exclusion criteria
were inability to measure BP in both arms (e.g. deﬁciency or
shunt), death within 1 month, or inability to keep track of or
participate in follow-up. After the exclusions, 1076 patients were
included for the analysis. There were no missing data during
follow-up. This was a development and validation study. An
independent data set was used to develop the model. Because of
the necessity of large number of development cohort, we deﬁned
700 randomly selected patients using a statistical software (SPSS
for Windows version 22.0; SPSS Inc., Chicago, IL, USA) as a
development cohort to conﬁrm that IAD was the predictor of
cardiovascular events and to determine optimal cut-off value of
IAD. Next, we validated outcomes in the remaining 376 patients as
a validation cohort [12,13]. The Institutional Review Board of the
Tokushima University Hospital approved the study protocol.
Blood pressure measurements
The BP measurements of both arms were done simultaneously
using the ankle-brachial BP index (ABI) form of automatic device
(Omron Healthcare, Kyoto, Japan) [14,15]. Measurements were
taken in the sequence of right arm, left arm, right ankle, and left
ankle and repeated twice in the supine position with appropriately
sized cuffs. First measurement is performed to estimate BP roughly
and synchronizes a phase at the pressurization of the cuffs, and
second measurement is performed subsequently for the actual
value. Therefore, this method has fewer random variations than a
method using two sphygmomanometers. The IAD was deﬁned as
the absolute difference of systolic BP of both arms. The maximal
difference between arms was used. The ABI and brachial-ankle
pulse wave velocity (baPWV) were measured after a 15-min rest
period in the supine position in an air-conditioned room using a
vascular testing device [16]. The ABI was calculated separately for
each leg, and the lower of the 2 ABI values was used for analysis and
the higher of the 2baPWV values was used for the analysis [17].
Clinical outcomes
The endpoints were obtained by reviewing all medical records
including the last hospitalization, nursing home records, and
personal physical records. Based on past studies, the primary
endpoint was cardiovascular event deﬁned as new onset of acute
myocardial infarction, angina, coronary restenosis, cerebral
infarction, cerebral hemorrhage, subarachnoid hemorrhage, tran-
sient ischemic attack, or peripheral arterial disease [18,19]. Each
diagnosis was based on a coronary angiography, coronary
computed tomography (CT), magnetic resonance imaging of the
brain, head CT or contrast vascular CT. The second endpoint was all-
cause mortality. The duration of follow-up began at the time of the
initial tests and ended in March 2016.Statistical analysis
Statistical analysis was performed using SPSS for Windows
(version 22.0; SPSS Inc., Chicago, IL, USA) [20]. Multiple logistic
regression analysis for Cox proportional hazards models was used
to predict a factor of cardiovascular events and all-cause mortality.
Signiﬁcant variables in univariate analysis (p < 0.05) were selected
as the covariates for multivariate analysis for Cox proportional
hazards models. A receiver operating characteristic curve (ROC)
was constructed on the basis of the sensitivity and speciﬁcity of the
predictions for cardiovascular events from the development
cohort. We determined the optimal cut-off value using Youden
index [21]. This optimal cut-off value was used to validate the
prediction of cardiovascular events. We divided a validation cohort
into two groups with the optimal cut-off value of IAD. An event-
free curve was estimated using the Kaplan–Meier method. The log-
rank test was used to compare the differences in event-free rates
between two groups. The differences between groups were
checked by Chi-square test for categorical variables or by
independent t test for continuous variables. To assess the
reproducibility of BP differences between arms, the second
measurements of BP using ABI-form was done in 50 randomly
selected patients. To evaluate the measurement accuracy about
this cut-off value, we used Pearson's correlation test. A value of
p < 0.05 was considered statistically signiﬁcant.
Results
Patient characteristics
One thousand and seventy six patients were enrolled in this
study. The purposes of measurement were a screening examina-
tion for arteriosclerotic disease (n = 770, 71.6%) and to rule out
peripheral arterial disease (n = 306, 28.4%). Patients in the
development cohort (n = 700) had a mean age of 72 years, 48%
were female. The comorbidities in this cohort were 69% of patients
with hypertension, 30% of patients had diabetes mellitus, 20% were
smokers, and 42% had dyslipidemia. Median IAD was 4 mmHg. In
the BP examination, 506 patients (72%) had no difference, less than
5 mmHg. Eighty-one patients (11%) were lower in the right arm,
and 113 patients (16%) were lower with the left arm. All patients in
the development cohort were followed for an average of
2.8  1.6 years. Patients in the validation cohort (n = 376) had a
mean age of 73 years, 42% were female. All patients in the
validation cohort were also followed for an average of
2.8  1.6 years. We show patient characteristics that compared
the development cohort with the validation cohort in Table 1. No
signiﬁcant differences were observed with regard to clinical
background between the two groups.
Development cohort
In the development cohort, 143 (20%) patients reached the
primary endpoint (cardiovascular events), and 78 (11%) patients
reached the secondary endpoint (all-cause death). The causes of
cardiovascular events were deﬁned as new onset of acute
myocardial infarction (n = 4, 3%), angina (n = 33, 23%), coronary
restenosis (n = 2, 1%), cerebral infarction (n = 27, 19%), cerebral
hemorrhage (n = 6, 4%), subarachnoid hemorrhage (n = 4, 3%),
transient ischemic attack (n = 6, 4%) and peripheral arterial disease
(n = 40, 28%).
In univariate analysis for Cox proportional hazards models, age,
IAD, diabetes mellitus, hypertension, smoking, ABI, baPWV,
hemoglobin, serum creatinine, low-density lipoprotein cholester-
ol, high-density lipoprotein cholesterol, hemoglobin A1c, brain
natriuretic peptide, diuretic, statin, and anti-platelet were
Table 1
Clinical characteristics in development and validation cohort.
Development cohort Validation cohort p-Value
Number 700 376 –
Age, years 72 12 73 11 0.324
Male gender (%) 362 (52) 217 (58) 0.06
Body mass index 23  4 23  4 0.753
Systolic BP, mmHg 131 19 132  22 0.641
Diastolic BP, mmHg 75 11 75 13 0.631
IAD, mmHg 4  5 4  4 0.925
Diabetes, n (%) 212 (30) 108 (29) 0.593
Hypertension, n (%) 480 (69) 269 (72) 0.312
Dyslipidemia, n (%) 295 (42) 138 (37) 0.083
Smoking, n (%) 140 (20) 89 (24) 0.161
Vascular function tests
ABI 1.09  0.16 1.07  0.17 0.053
baPWV, cm/s 1928  567 1951 788 0.614
Laboratory data
Hemoglobin, g/dl 13.4 1.8 13.4  2.0 0.849
Serum creatinine, mg/dl 0.94  0.79 0.94  0.43 0.925
LDL-C, mg/dl 107  34 103  32 0.174
HDL-C, mg/dl 57  16 57  16 0.604
Triglyceride, mg/dl 132  96 126  76 0.303
Hemoglobin A1c, % 6.2 1.3 6.1 1.2 0.229
BNP, pg/dl 112  250 113  223 0.914
Medication
ARB/ACE-I, n (%) 316 (45) 187 (50) 0.150
b-Blocker, n (%) 138 (20) 77 (21) 0.765
CCB, n (%) 348 (50) 196 (52) 0.450
Diuretic, n (%) 158 (23) 96 (26) 0.276
Statin, n (%) 263 (38) 144 (38) 0.815
Anti-platelet, n (%) 337 (48) 197 (52) 0.184
Warfarin, n (%) 57 (8) 40 (11) 0.173
Data are presented as number of patients (percentage) or mean  SD.
BP, blood pressure; IAD, inter-arm systolic blood pressure difference; ABI,
ankle-brachial blood pressure index; baPWV, brachial-ankle pulse wave
velocity; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol; BNP, brain natriuretic peptide; ARB, angiotensin II
receptor blocker; ACE-I, angiotensin-converting enzyme inhibitor; CCB, calcium
channel blocker.
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Cox proportional hazards analysis with stepwise forward regres-
sions, seven factors were selected in the ﬁnal model and IAD was
the strong predictor of cardiovascular events (hazard ratio: 1.03,
95% conﬁdence interval: 1.01–1.05, p = 0.005, Table 3). Diabetes did
not remain probably in the multivariate analysis for clinical events
because glycemic control was good (hemoglobin A1c: 6.2  1.3%)
[22]. Interestingly, in univariate analysis for Cox proportional
hazards models, IAD was not associated with all-cause mortality
(Table 3). Fig. 1 shows the ROC curve to obtain the cut-off value of
IAD for cardiovascular events from the development cohort. This
ROC curve revealed that 5 mmHg was the optimal cut-off point of
IAD (area under the curve: 0.598, 95% conﬁdence interval: 0.543–
0.652, p < 0.001, Fig.1). In the development cohort, IAD 5 mmHg or
more was found in 81 patients in right arms (42%) and 114 patients
in left arms (58%). However, there were no signiﬁcant differences
with arms laterality of IAD in the cardiovascular events (p = 0.17)
and all-cause mortality (p = 0.79). Thus, the arms laterality of IAD
was not important to predict cardiovascular event and the absolute
value of IAD itself was associated with cardiovascular events.
Reproducibility about cut-off value of IAD
In the 50 randomly selected patients, the correlation between
1st and 2nd measurements of IAD was good (R = 0.75, p < 0.001,
Supplement 1A). Importantly, 46 patients (92%) had IAD differ-
ences between 1st and 2nd measurements within 4 mmHg. Only
two patients (red lines in Supplement 1B) with low IAD
(<5 mmHg) at 1st measurement had high IAD at 2nd measure-
ment (5 mmHg) and two patients with high IAD at 1stmeasurement had low IAD at 2nd measurement (blue lines in
Supplement 1B).
Validation cohort with event-free survival
In the validation cohort, 78 (21%) patients reached the primary
endpoint (cardiovascular events), and 40 (11%) patients reached
the secondary endpoint (all-cause death). In the validation cohort,
we conducted the multivariate Cox proportional hazards analysis
for the prediction of cardiovascular events and all-cause mortality,
shown in Table 4. The IAD was shown to be the predictor of
cardiovascular events; hazard ratio of cardiovascular events was
1.04 (95% conﬁdence interval; 1.01–1.07, p = 0.016). However, the
IAD was not associated with the all-cause mortality. The cut-off
value obtained from ROC curve was the same: 5 mmHg (area under
the curve: 0.591, 95% conﬁdence interval: 0.520–0.663, p = 0.013).
We divided a validation cohort into two groups of a large IAD group
(Group L: IAD 5 mmHg) and small IAD group (Group S:
IAD < 5 mmHg). There were no differences in clinical character-
istics including antihypertensive therapy between two groups
(Table 5). Fig. 2A illustrates the event-free survival of cardiovascu-
lar events compared Group L with Group S. Group L had
signiﬁcantly shorter event-free survival of cardiovascular events
than Group S in a statistical signiﬁcance (p = 0.02). On the other
hand, there were no signiﬁcant differences in event-free survival
curves of all-cause mortality (Fig. 2B, p = 0.781).
Discussion
Our development and validation cohort data showed that the
IAD was a signiﬁcant independent predictor of cardiovascular
events in patients with risks of cardiovascular disease. An IAD
5 mmHg was associated with cardiovascular events in both
cohorts. This result suggested that IAD plays an important role for
the outcome of this high-risk cohort in daily clinical practice.
Prevalence of IAD
The prevention of major cardiovascular and cerebrovascular
events remains a serious public health problem. The IAD is
expected to be a simple, easy, and economical parameter that can
be measured with no additional equipment to screen patients for
cardiovascular disease [23]. The IAD is regularly found in clinical
practice. From community based studies, IAD 10 mmHg are seen
in 5.8–9.2% of people with hypertension [6]. This report of
prevalence of IAD is consistent with our results. Our study reported
that there were 314 patients (29%) who had a BP difference of
5 mmHg or more, and only 62 patients (6%) who had a BP
difference of 10 mmHg or more. This ﬁnding emphasized the
importance of ﬁnding the IAD in clinical practice, because many
cases (29%) had IAD of 5 mmHg in patients with risks of
cardiovascular disease in the Japanese cohort.
Measurement of IAD
Measurement of BP in both arms is important. However, in the
guidelines of the Japanese Hypertensive Society, there were a few
mentions for measuring the IAD [4]. In the clinical setting,
simultaneous measurements of BP using an automatic device were
possible, and manual measurement of BP is subject to bias of
interpretation among observers [24,25]. BP data obtained during
ABI examination may provide more consistent data for use of IAD.
ABI is a widely used clinical test for the assessment of peripheral
arterial disease and is an indicator of generalized atherosclerosis
[22–24]. IAD had also a prognostic value independent of ABI from
our multivariate Cox proportional hazards models. Our ﬁndings
Table 2
Univariable association of primary and secondary outcomes in development cohort.
Primary endpoint Secondary endpoint
Hazard ratio
(95% conﬁdence interval)
p-Value Hazard ratio
(95% conﬁdence interval)
p-Value
Age 1.02 (1.01–1.04) 0.009 1.09 (1.06–1.12) <0.001
Male gender 1.27 (0.91–1.77) 0.157 1.13 (0.72–1.76) 0.601
Body mass index 0.98 (0.94–1.03) 0.391 0.88 (0.82–0.94) <0.001
Systolic BP 1.01 (1.00–1.02) 0.143 0.99 (0.98–1.00) 0.153
Diastolic BP 1.01 (1.00–1.03) 0.185 0.99 (0.97–1.01) 0.208
IAD 1.05 (1.03–1.07) <0.001 1.00 (0.95–1.04) 0.909
Diabetes 0.49 (0.35–0.68) <0.001 0.91 (0.57–1.46) 0.697
Hypertension 0.66 (0.45–0.98) 0.04 1.10 (0.68–1.77) 0.714
Dyslipidemia 0.99 (0.71–1.38) 0.961 2.35 (1.40–3.93) 0.001
Smoking 0.68 (0.46–0.99) 0.045 0.57 (0.35–0.92) 0.022
Vascular function tests
ABI 0.14 (0.07–0.31) <0.001 0.10 (0.04–0.25) <0.001
baPWV 1.01 (1.00–1.01) <0.001 1.01 (1.00–1.01) <0.001
Laboratory data
Hemoglobin 0.88 (0.81–0.97) 0.009 0.71 (0.63–0.80) <0.001
Serum creatinine 1.20 (1.09–1.33) <0.001 1.16 (1.03–1.32) 0.016
LDL-C 0.99 (0.99–1.00) 0.027 0.99 (0.98–1.00) 0.012
HDL-C 0.98 (0.97–0.99) <0.001 0.99 (0.97–1.00) 0.107
Triglyceride 1.00 (1.00–1.00) 0.53 1.00 (0.99–1.00) 0.249
Hemoglobin A1c 1.11 (1.01–1.22) 0.027 0.82 (0.65–1.04) 0.105
BNP 1.01 (1.00–1.01) <0.001 1.01 (1.00–1.01) <0.001
Medication
ARB/ACE-I 0.87 (0.63–1.21) 0.397 1.34 (0.85–2.10) 0.206
b-Blocker 0.78 (0.53–1.15) 0.213 0.59 (0.36–0.95) 0.029
CCB 1.07 (0.77–1.48) 0.7 1.48 (0.94–2.33) 0.089
Diuretic 0.50 (0.36–0.71) <0.001 0.27 (0.17–0.42) <0.001
Statin 0.66 (0.47–0.91) 0.012 1.44 (0.89–2.31) 0.137
Anti-platelet 0.35 (0.24–0.50) <0.001 0.67 (0.42–1.05) 0.081
Warfarin 0.71 (0.42–1.20) 0.201 0.28 (0.17–0.47) <0.001
BP, blood pressure; IAD, inter-arm systolic blood pressure difference; ABI, ankle-brachial blood pressure index; baPWV, brachial-ankle pulse wave velocity; LDL-C, low-
density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BNP, brain natriuretic peptide; ARB, angiotensin II receptor blocker; ACE-I, angiotensin-
converting enzyme inhibitor; CCB, calcium channel blocker.
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large IAD when assessing an ABI examination.
Prediction for cardiovascular events
Several papers showed that IAD were associated with elevated
cardiovascular event rates [25–27]. Evidence for this association is
derived from a number of cohort studies and the meta-analysis
conﬁrmed these results. However, the relevant cut-off value of IAD
on long-term clinical outcomes has not been sufﬁciently evaluated.
Previous papers suggested that 10 mmHg or 15 mmHg is a good
cut-off value to predict cardiovascular events [26]. However, there
were very few cases with the difference in BP of 10 mmHg inTable 3
Multi-variable associations of primary and secondary outcomes in development cohor
Primary endpoint 
Hazard ratio
(95% conﬁdence interval)
p-
Age 
IAD 1.03 (1.01–1.05) 0.
ABI 0.29 (0.12–0.72) 0.
baPWV 1.01 (1.00–1.01) <
Hemoglobin 
HDL-C 0.97 (0.96–0.99) <
Hemoglobin A1c 1.13 (1.02–1.26) 0.
BNP 1.01 (1.00–1.01) <
Diuretic use 
Anti-platelet use 0.43 (0.29–0.65) <
Warfarin use 
IAD, inter-arm systolic blood pressure difference; ABI, ankle-brachial blood pressure in
cholesterol; BNP, brain natriuretic peptide.routine practice, and a clinically optimal cut-off value would be
needed. The ROC curve in our study revealed that 5 mmHg was the
best cut-off points of IAD to predict cardiovascular events.
However, 5 mmHg was a small different systolic BP of both arms.
Therefore we evaluated the reproducibility of IAD. In our study, the
correlation between 1st and 2nd measurements of IAD was good,
furthermore IAD of many patients showed less than 5 mmHg
(72%). According to these results, this cut-off value of IAD
(5 mmHg) was not random variation, and acceptable to assess
the prognosis in the clinical setting [27,28]. In the present study,
the sample size was relatively large. Also, unlike previous studies,
the analysis including the development and validation cohort
conﬁrmed the cut-off value of IAD [29].t.
Secondary endpoint
Value Hazard ratio
(95% conﬁdence interval)
p-Value
1.05 (1.01–1.08) 0.005
005
007 0.22 (0.08–0.64) 0.006
0.001
0.80 (0.69–0.92) 0.002
0.001
018
0.001 1.01 (1.00–1.01) 0.002
0.55 (0.33–0.90) 0.018
0.001
0.50 (0.28–0.88) 0.016
dex; baPWV, brachial-ankle pulse wave velocity; HDL-C, high-density lipoprotein
Fig. 1. Receiver operating characteristic curve of inter-arm systolic blood pressure
difference for incidence of cardiovascular events in the development cohort.
Table 5
Comparison of patient characteristics between two groups with IAD in validation
cohort.
Group S:
IAD <5 mmHg
Group L:
IAD 5 mmHg
p-Value
Number 256 120 –
Age, years 73 11 72 12 0.494
Male gender (%) 150 (59) 67 (56) 0.614
Body mass index 23  4 24  4 0.067
Systolic BP, mmHg 131 21 134  22 0.084
Diastolic BP, mmHg 75 13 76  13 0.929
IAD, mmHg 2 1 8  5 <0.001
Diabetes, n (%) 64 (25) 44 (37) 0.02
Hypertension, n (%) 179 (70) 90 (75) 0.309
Dyslipidemia, n (%) 85 (33) 53 (44) 0.04
Smoking, n (%) 65 (25) 24 (20) 0.252
Vascular function tests
ABI 1.07  0.16 1.05  0.20 0.257
baPWV, cm/s 1897 688 2065  961 0.055
Laboratory data
Hemoglobin, g/dl 13.3  2.0 13.4 1.9 0.332
Serum creatinine, mg/dl 0.94  0.41 0.95  0.48 0.762
LDL-C, mg/dl 103  33 102  30 0.801
HDL-C, mg/dl 57  16 57  17 0.920
Triglyceride, mg/dl 124 78 131 70 0.443
Hemoglobin A1c, % 6.0  1.1 6.3 1.3 0.076
BNP, pg/dl 112 190 116  284 0.884
Medication
ARB/ACE-I, n (%) 127 (50) 60 (50) 0.944
b-Blocker, n (%) 48 (19) 29 (24) 0.225
CCB, n (%) 129 (50) 67 (56) 0.325
Diuretic, n (%) 67 (26) 29 (24) 0.678
Statin, n (%) 96 (38) 48 (40) 0.642
Anti-platelet, n (%) 130 (51) 67 (56) 0.361
Warfarin, n (%) 31 (12) 9 (8) 0.177
BP, blood pressure; IAD, inter-arm systolic blood pressure difference; ABI,
ankle-brachial blood pressure index; baPWV, brachial-ankle pulse wave
velocity; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol; BNP, brain natriuretic peptide; ARB, angiotensin II
receptor blocker; ACE-I, angiotensin-converting enzyme inhibitor; CCB, calcium
channel blocker.
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There are some possible explanations for the signiﬁcant
association between IAD and increased cardiovascular events.
Hypertensive patients with a large IAD may be misdiagnosed as
normal or controlled BP, because of incorrectly measured BP
[5,30]. In addition, one previous study showed that IAD was
associated with increased aortic stiffness and left ventricular
hypertrophy [31]. This result suggested that a large IAD might be
associated with peripheral arterial disease and contribute to the
poor prognosis. On the other hand, a large IAD was not associated
with all-cause mortality in our cohort. Some possible explanations
for this discrepancy include many causes of death in the Japanese
population. In addition, one possible explanation was the inﬂuence
of medications. Our patients had several medications including
beta-blocker, statin, or antiplatelet drugs. The use of these
medications might inﬂuence the association between IAD and
all-cause mortality. Further studies to assess the effect of
medications for the all-cause mortality should be needed. The
IAD is a simple marker, and it is suitable for detection of occult
atherosclerosis, but it may not be useful to detect other causes of
death (e.g. cancer or infection).
Clinical implications
To the best of our knowledge, this is one of the largest studies
evaluating the prognostic utility of IAD in the Japanese population.Table 4
Multi-variable associations of primary and secondary endpoint in validation cohort.
Primary endpoint 
Hazard ratio
(95% conﬁdence interval)
p-
Age 
IAD 1.03 (1.01–1.07) 0.
ABI 0.18 (0.07–0.47) <
BNP 
Diuretic use 
Anti-platelet use 0.47 (0.28–0.81) 0.
IAD, inter-arm systolic blood pressure difference; ABI, ankle-brachial blood pressureThis result suggested that a certain threshold of IAD (5 mmHg) was
important in prognosis. The inter-arm difference of BP is a simple,
reproducible, and inexpensive method for stratifying this high-risk
group with cardiovascular disease. However, this cut-off value
should be tested on an international large cohort of patients with
high risk for cardiovascular disease to predict cardiac events.
Study limitations
There were several limitations to this study. Due to the fact that
we enrolled only patients with cardiovascular risks, the results of
the present study may not be extrapolated to the general population
and should be applied to speciﬁc subjects with lifestyle-related
diseases. Additionally, because the aim of this prospective studySecondary endpoint
Value Hazard ratio
(95% conﬁdence interval)
p-Value
1.08 (1.03–1.13) 0.001
043
0.001
1.01 (1.00–1.01) 0.02
0.39 (0.20–0.76) 0.006
006
 index; BNP, brain natriuretic peptide.
Fig. 2. Kaplan–Meier analysis for cardiovascular events (A) and all-cause death (B)
in the validation cohort. Patients with higher IAD (cut-off value: 5 mmHg) had a
signiﬁcantly higher incidence of cardiovascular events. IAD, inter-arm systolic blood
pressure difference.
A. Hirono et al. / Journal of Cardiology 71 (2018) 24–30 29was to assess the utility of the inter-arm difference of BP, other
assessments for cardiovascular risks (e.g. carotid ultrasound) were
not enrolled in the study from the beginning.
Conclusions
IAD is signiﬁcantly associated with future cardiovascular events
in high-risk patients with cardiovascular disease. The optimal cut-
off value of IAD is 5 mmHg from our development and validation
cohorts.
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